主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

北京中医药大学学报 ›› 2015, Vol. 38 ›› Issue (6): 420-425.doi: 10.3969/j.issn.1006-2157.2015.06.012

• 临床研究 • 上一篇    下一篇

大黄庶虫丸治疗慢性乙型肝炎的系统评价*

邓艳芳,屈乐,宋亚南,蒋燕#   

  1. 北京中医药大学基础医学院 北京 100029
  • 收稿日期:2014-12-25 出版日期:2015-06-15 发布日期:2015-06-15
  • 通讯作者: 蒋燕,女,博士,教授,硕士生导师,研究方向:名医名方的临床应用研究,E-mail:jy7232@126.com
  • 作者简介:邓艳芳,女,在读硕士生
  • 基金资助:
    *北京市朝阳区协同创新资助项目(No.XC1420)

Dahuang Zhechong Wan for chronic hepatitis B: a systematic review*

DENG Yan-fang, QU Le, SONG Ya-nan, JIANG Yan#   

  1. School of Preclinical Medicine, Beijing University of Chinese Medicine, Beijing 100029
  • Received:2014-12-25 Online:2015-06-15 Published:2015-06-15

摘要: 目的 评价大黄虫丸治疗慢性乙型肝炎患者(CHB)的有效性。方法 检索并筛选国内外期刊公开发表的大黄虫丸治疗CHB的随机对照试验(RCT),采用RevMan5.2软件对肝功能疗效、肝纤维化疗效等进行Meta分析。结果 共纳入21篇RCT。大黄虫丸独立应用0篇,联合应用21篇,合计1 731例,其中实验组875例,对照组856例。Meta分析结果显示,大黄虫丸联合应用组患者治疗后临床总有效率、HBeAg转阴率、HBV-DNA转阴率、谷草转氨酶(AST)、总胆红素(TBil)优于对照组,且差异有统计学意义。结论 治疗CHB,联合大黄虫丸组优于未联合大黄虫丸组。但受研究文献的质量影响,此结论还需高质量的文献进一步验证。

关键词: 大黄虫丸, 慢性乙型肝炎, 随机对照试验, 系统评价

Abstract: Objective To evaluate the effectiveness of Dahuang Zhechong Wan (Rhubarb and Eupolyphaga Pill) for Chronic Hepatitis B. Methods Randomized controlled trials (RCTs) of Dahuang Zhechong Wan for Chronic Hepatitis B published in domestic or foreign magazines were searched. Revman5.2 was used to perform the Meta-analysis on the curative effect of Dahuang Zhechong Wan for chronic hepatitis B. Results A total of 21 RCTs were included, among which none used Dahuang Zhechong Wan only.21 studies all used combined treatment on 1731 cases with 875 in treatment groups and 856 in control groups. The results of meta-analyses showed that at the end of the treatment, groups adding Dahuang Zhechong Wan was superior to those without. There were significant difference in both the clinical efficiency, HBV-DNA negative conversion, HBeAg negative conversion, ALT and TBil recovery. Conclusion Combined therapy using Dahuang Zhechong Wan is superior to conventional medicine alone for chronic hepatitis B. However, because of low quality of the included studies, high-quality and large-scale RCTs are needed to provide further evidence.

Key words: Dahuang Zhechong Wan, chronic hepatitis B, randomized controlled trial, systematic review

中图分类号: 

  • R256.4